Olema Pharmaceuticals (OLMA) Valuation After Encouraging New OP-3136 Phase 1 Data
Olema Pharmaceuticals (OLMA) recently released promising initial Phase 1 data for its KAT6 inhibitor OP-3136, showing acceptable tolerability and tumor shrinkage in solid tumors. Despite a 44% year-to-date share price drop, a Discounted Cash Flow (DCF) model by Simply Wall St suggests a fair value of $183.53, indicating significant undervaluation compared to its current price of $14.06, though risks like lack of revenue and clinical uncertainty remain. The article encourages investors to analyze the data, weighing these risks against the potential for growth.
Olema reports phase 1 data for cancer drug OP-3136
Olema Pharmaceuticals, Inc. announced preliminary positive Phase 1 clinical data for its cancer drug OP-3136, a lysine acetyltransferase 6 inhibitor, showing no dose-limiting toxicities and tumor shrinkage in 13 out of 19 evaluable patients. The shares rose following the announcement, and the data will be presented at the American Society of Clinical Oncology Annual Meeting. The company also faces a GAAP net loss for Q4 and full-year 2025, while analysts hold mixed but largely positive ratings on its stock.
Olema Oncology (NASDAQ: OLMA) shares early OP-3136 Phase 1 cancer data
Olema Pharmaceuticals reported encouraging preliminary Phase 1 data for its oral KAT6 inhibitor, OP-3136, in 32 heavily pretreated patients with advanced solid tumors. The study showed OP-3136 was well-tolerated with no dose-limiting toxicities and demonstrated anti-tumor activity, including tumor shrinkage in 13 patients and 3 partial responses. These early results support the continued development of OP-3136 as both a monotherapy and in combination with other treatments.
Early cancer trial sees tumor shrinkage in 13 of 19 on Olema drug
Olema Oncology reported encouraging initial Phase 1 data for its oral KAT6 inhibitor, OP-3136, in patients with advanced solid tumors. The drug demonstrated acceptable tolerability with no dose-limiting toxicities and showed promising anti-tumor activity, including tumor shrinkage in 13 of 19 evaluable patients and three partial responses. These findings support further development of OP-3136 as monotherapy and in combination with other treatments.
Olema Oncology Announces Encouraging Initial Clinical Data
Olema Oncology announced encouraging initial clinical data from its Phase 1 study of OP-3136, a KAT6 inhibitor, showing it was well-tolerated with promising anti-tumor activity across multiple solid tumor types. The study observed tumor shrinkage in over two-thirds of evaluable patients and demonstrated on-target engagement. These results support the continued development of OP-3136 as a monotherapy and in combination with other treatments for difficult-to-treat cancers.
Olema Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Olema Pharmaceuticals announced its participation in multiple investor conferences, including the TD Cowen 7th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference, and Goldman Sachs 47th Annual Global Healthcare Conference, to discuss its targeted therapies for breast cancer. The company is advancing palazestrant (OP-1250) in two Phase 3 trials and OP-3136 in a Phase 1 study. Live webcasts of these presentations will be available on Olema's investor relations website.
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology (Nasdaq: OLMA) announced its participation in three upcoming investor conferences in May and June 2026: the TD Cowen 7th Annual Oncology Innovation Summit (May 26), the Jefferies Global Healthcare Conference (June 3), and the Goldman Sachs 47th Annual Global Healthcare Conference (June 9). The company will present in fireside chats at these virtual and in-person events. Live webcasts of these presentations will be available on Olema's investor relations website.
Breast cancer-focused Olema plans 3 investor talks across May and June
Olema Oncology (Nasdaq: OLMA), a biopharmaceutical company specializing in breast cancer therapies, has announced its participation in three upcoming investor conferences in May and June 2026. These events include the TD Cowen Oncology Innovation Summit, Jefferies Global Healthcare Conference, and Goldman Sachs Global Healthcare Conference, where company representatives will engage in fireside chats. Webcasts of these presentations will be available via Olema’s investor relations website, contingent on host permissions.
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $52
J.P. Morgan has reiterated its Buy rating for Olema Pharmaceuticals (OLMA.US), setting a target price of $52. This indicates a positive outlook from the analyst firm regarding the company's stock performance.
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology, a clinical-stage biopharmaceutical company focused on breast cancer therapies, announced its participation in three upcoming investor conferences in May and June 2026. The company will present in fireside chats at the TD Cowen 7th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference, and Goldman Sachs 47th Annual Global Healthcare Conference. Live webcasts of these presentations will be available on Olema's investor relations website.
What Prompted the Chief Legal Officer's Recent OLMA Share Sales?
Olema Pharmaceuticals' Chief Legal Officer, Shawnte Mitchell, fully liquidated her direct holdings, selling shares worth $600,600, as part of a trend of executive divestment after the stock's 300% surge. Despite insider selling and CFO turnover, the company is advancing its lead candidate, palazestrant, into Phase 3, a move supported by positive industry validation for oral SERDs. The upcoming OPERA-01 Phase 3 data readout in H2 2026 is a critical binary event that will heavily influence the company's future valuation and investor sentiment.
Olema Pharmaceuticals (OLMA) Deepens Trial Spend With Ample Cash Buffer Is Its Risk-Reward Now Clearer?
Olema Pharmaceuticals (OLMA) reported a Q1 2026 net loss of US$53.09 million due to increased spending on late-stage breast cancer trials, but maintained a strong cash balance of US$505.3 million. The company is focused on pivotal Phase 3 palazestrant data and initial OP-3136 results at ASCO 2026, which are key near-term catalysts for its investment narrative. Despite a wider loss, Olema's substantial cash reserves are intended to support its pipeline development, though execution risk and sustained losses remain considerations given the absence of revenue.
Olema Pharmaceuticals (OLMA) loses 33.4% in 4 weeks, here's why a trend reversal may be around the corner
Olema Pharmaceuticals (OLMA) has experienced a significant 33.4% decline over the past four weeks, underperforming the broader Oils-Energy sector and the S&P 500. Despite this recent downturn, the article suggests that a trend reversal might be imminent due to the stock's oversold status, as indicated by its Relative Strength Index (RSI) of 29.89. This oversold condition frequently precedes a bounce in stock prices.
Olema Pharmaceuticals | SCHEDULE 13G/A: Others
This article indicates that Olema Pharmaceuticals has filed a SCHEDULE 13G/A document, typically associated with reporting beneficial ownership of a company's stock. The 'Others' classification often implies a group of filers rather than a single entity. Further details would be within the document itself.
Janus Henderson (NASDAQ: OLMA) discloses 7.11M shares, 8.2% stake
Janus Henderson Group plc has reported a beneficial ownership of 7,108,488 shares, equating to an 8.2% stake in Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), through an amended Schedule 13G/A filing. The asset managers within Janus Henderson exercise shared voting and shared dispositive power over these shares, acting on behalf of various Managed Portfolios. This disclosure reflects a passive institutional position, and Janus Henderson disclaims any rights to dividends or sale proceeds from these securities.
Bain Capital (OLMA) discloses 8.2% position including pre-funded warrant
Bain Capital Life Sciences Opportunities IV, L.P. has disclosed an 8.2% stake in Olema Pharmaceuticals (OLMA) through an amended Schedule 13G/A filing. This position includes 2,960,036 directly held shares and a pre-funded warrant for 4,513,202 shares, with a beneficial ownership cap preventing exercise beyond 9.99%. The filing indicates shared voting and dispositive power among related Bain entities over 7,473,238 shares.
Assessing Olema Pharmaceuticals (OLMA) Valuation After Wider Q1 Loss And Late‑Stage Trial Updates
Olema Pharmaceuticals (OLMA) reported a wider Q1 net loss of US$53.09 million, driven by increased clinical spending, and its shares have seen a significant recent decline despite a strong long-term return. A Discounted Cash Flow (DCF) model suggests the stock is significantly undervalued at $185.42 per share compared to its current price of $13.82, based on theoretical future cash flows from its pipeline. However, this valuation is highly sensitive to clinical trial outcomes and potential future commercialization complexities for its lead drug, palazestrant, warranting careful consideration of risks.
Olema Pharmaceuticals (OLMA) loses 33.4% in 4 weeks, here's why a trend reversal may be around the corner
Olema Pharmaceuticals (OLMA) has experienced a significant 33.4% decline in its stock price over the past four weeks. This article suggests that a trend reversal for OLMA may be imminent, providing insights into potential reasons for a recovery. Investors following the pharmaceutical sector, especially small-cap growth stocks, should pay close attention to this analysis.
Goldman Sachs Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Cuts Target Price to $23
Goldman Sachs has reaffirmed its Buy rating for Olema Pharmaceuticals (OLMA.US) but has adjusted its price target downwards to $23. This revised target suggests a potential for significant upside from the stock's last closing price.
OLMA Maintained by Guggenheim -- Price Target Lowered to $35.00
Guggenheim has maintained a 'Buy' rating for Olema Pharmaceuticals (OLMA) but adjusted its price target downward from $38.00 to $35.00, suggesting cautious optimism. The company, focused on women's cancer therapies, has a GF Score™ of 36/100 and has seen significant insider selling in the last three months, raising concerns about profitability and growth despite analyst confidence. Investors are advised to consider these factors when evaluating OLMA stock.
Pushed out by AI in S.F., a cancer-focused biotech regroups with new space in South City
Olema Pharmaceuticals, a cancer-focused biotech company, has secured new office space in South San Francisco after being pushed out of its former San Francisco location by OpenAI. The company is actively hiring for 20 open positions as it prepares for a potential commercial launch, highlighting the impact of AI growth on real estate in the Bay Area.
Press Release: Olema Oncology Reports First Quarter 2026 Financial and Operating Results
Olema Oncology announced its first-quarter 2026 financial and operating results. The company reported on its financial performance and provided updates on its operational progress for the quarter.
Olema Pharmaceuticals Q1 Net Loss Widens
Olema Pharmaceuticals reported a wider net loss in the first quarter of 2026 compared to the previous year, with net loss attributable to common stockholders increasing to $36.0 million from $26.8 million. This was primarily due to higher research and development expenses, which rose to $31.0 million. The company's cash and equivalents stood at $192.5 million as of March 31, 2026.
Olema Pharmaceuticals: Differentiated KAT6i and Palazestrant Pipeline Catalysts Underpin Buy Rating
TD Cowen analyst Tyler Van Buren has maintained a Buy rating on Olema Pharmaceuticals (OLMA) due to its differentiated pipeline and upcoming catalysts. The analyst highlights the importance of initial OP-3136 KAT6 inhibitor data at ASCO, particularly its potential for a cleaner safety profile and antitumor activity in various cancers, especially in combination with palazestrant. Additionally, the forthcoming Phase III OPERA-01 readout for palazestrant in the fall contributes to a favorable risk-reward profile, reinforcing the Buy recommendation.
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating
TD Cowen has reiterated its Buy rating on Olema Pharmaceuticals (OLMA.US). The financial institution continues to show confidence in the company's stock.
Olema Pharmaceuticals Releases Q1 2026 Financial Results
Olema Pharmaceuticals reported a narrower-than-expected loss of $0.52 per share for Q1 2026, beating the estimated loss of $0.54 per share. Despite a widening net loss of $53.1 million compared to the previous year, common for pre-commercial biotech firms, Wall Street analysts maintain an optimistic outlook with 10 buy ratings. The company continues to advance therapies for women's cancers, supporting the bullish sentiment among investors.
Olema Pharmaceuticals, Inc. Q1 2026: Net income $(53.1)M, EPS $(0.52) — 10-Q Summary
Olema Pharmaceuticals, Inc. reported a Q1 2026 net loss of $(53.1)M, equating to a diluted loss per share of $(0.52), which is an increase in loss compared to Q1 2025. The company remains pre-revenue but is advancing its pipeline with Palazestrant in Phase 3 trials and OP-3136 in Phase 1, alongside preparations for potential commercialization.
Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q1 Net Loss $0.52 a Share, vs. FactSet Est of $0.52 Loss
Olema Pharmaceuticals (OLMA) reported a Q1 net loss of $0.52 per share, matching FactSet's estimated loss of $0.52. This announcement was made on May 12, 2026. The company is a clinical-stage biopharmaceutical firm focused on breast cancer treatments.
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
Olema Oncology reported its financial and operating results for the first quarter ended March 31, 2026, highlighting significant advancements in its pipeline. The company anticipates top-line data from its Phase 3 OPERA-01 trial this fall and will present initial clinical data from the OP-3136 Phase 1 study at ASCO. Olema ended the quarter with $505.3 million in cash, cash equivalents, and marketable securities, with a net loss of $53.1 million due to increased spending on clinical development.
Olema Oncology (NASDAQ: OLMA) boosts trial spending ahead of key 2026 data
Olema Oncology reported its Q1 2026 results, showing a strong cash position of $505.3 million but an increased net loss of $53.1 million due to heightened investment in late-stage clinical trials. The company is accelerating spending on its palazestrant breast cancer programs, with pivotal Phase 3 OPERA-01 data expected in fall 2026 and initial Phase 1 data for OP-3136 at ASCO. Olema aims for its first commercial launch next year, driven by these upcoming clinical milestones.
Palazestrant nears pivotal Phase 3 data in metastatic breast cancer
Olema Oncology reported its first-quarter 2026 financial results, ending the quarter with $505.3 million in cash and securities, despite an increased net loss of $53.1 million due to higher R&D and G&A expenses. The company also provided updates on its clinical pipeline, with top-line data from the pivotal Phase 3 OPERA-01 trial for palazestrant monotherapy expected in fall 2026, and initial clinical data for OP-3136's Phase 1 study to be presented at ASCO 2026. Olema continues to enroll patients in the OPERA-02 trial, evaluating palazestrant in combination with ribociclib for metastatic breast cancer.
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
Olema Oncology reported its first-quarter 2026 financial and operating results, highlighting continued progress in its clinical trials for breast cancer therapies. The company anticipates top-line data from its Phase 3 OPERA-01 trial this fall and will present initial clinical data for OP-3136 at ASCO. Olema ended the quarter with $505.3 million in cash, cash equivalents, and marketable securities, despite an increased net loss due to higher R&D spending.
Olema earnings on deck: Cash burn, Phase 3 trial progress in focus
Olema Pharmaceuticals Inc. is set to report first-quarter results, with investors keenly watching its cash burn rate and progress in pivotal Phase 3 trials for palazestrant, its lead breast cancer drug candidate. The company is expected to post a wider loss of 53 cents per share, but Wall Street maintains a bullish "strong buy" rating with a mean price target suggesting significant upside. Key investor focus will be on the company's financial runway, updates from the OPERA-01 and OPERA-02 trials, and early clinical data for its pipeline candidate, OP-3136.
How Investors May Respond To Olema Pharmaceuticals (OLMA) Adding Biopharma Deal-Maker Prakash Raman To Board
Olema Pharmaceuticals has appointed Prakash Raman, a biopharma deal-maker, to its Board of Directors, which could influence the company's investment narrative and partnering options. While Raman's expertise is seen as incrementally helpful for business development and capital raising, the core investment case for Olema still hinges on clinical execution of its ER+/HER2- breast cancer franchise and managing balance sheet risk, as the company currently has no revenue and recurring losses. Investors are encouraged to consider multiple viewpoints on Olema's future given the varied fair value estimates and trial-heavy catalyst path.
Pier Capital LLC Decreases Position in Olema Pharmaceuticals, Inc. $OLMA
Pier Capital LLC significantly reduced its stake in Olema Pharmaceuticals (NASDAQ:OLMA) by 73.3% in the fourth quarter, selling 384,148 shares and retaining 140,101 shares valued at $3.50 million. While Pier Capital decreased its holdings, other institutional investors like Jennison Associates and Vanguard Group increased their positions, resulting in hedge funds and institutions collectively owning about 91.78% of the company's outstanding shares. Despite the company being unprofitable, analysts have a "Moderate Buy" consensus rating with an average target price of $44.40.
Assessing Olema Pharmaceuticals (OLMA) Valuation After A Year Of Strong Returns And Recent Share Price Weakness
Olema Pharmaceuticals (OLMA) has experienced mixed returns, with a 44.42% decline in the last three months but a 218.26% gain over the past year. Despite its current P/B ratio of 2.7x, which is higher than the broader industry average, analysts suggest it could be undervalued. A Discounted Cash Flow (DCF) model indicates a significant discount to its estimated future cash flow value, raising questions about whether market risks are overstated or the DCF is too optimistic.
Assessing Olema Pharmaceuticals (OLMA) Valuation After A Year Of Strong Returns And Recent Share Price Weakness
Olema Pharmaceuticals (OLMA) has experienced mixed returns, with a 44.42% decline over the past three months contrasting with a 218.26% gain over the past year. Despite a seemingly expensive price-to-book ratio of 2.7x compared to the broader biotech industry, a discounted cash flow (DCF) model suggests the stock is trading at a significant discount, raising questions about market perceptions of risk versus future cash flow potential.
Assessing Olema Pharmaceuticals (OLMA) Valuation After A Year Of Strong Returns And Recent Share Price Weakness
Olema Pharmaceuticals (OLMA) has seen strong returns over the past year but recent share price weakness, leading to questions about its valuation. While its price-to-book ratio appears high compared to the broader biotech industry, a discounted cash flow model suggests the stock may be deeply undervalued. The article prompts investors to consider if the market is overstating risks or if the DCF model is too optimistic, offering both positive and cautionary signals.
Olema Pharmaceuticals (OLMA) Expected to Announce Quarterly Earnings on Tuesday
Olema Pharmaceuticals (OLMA) is scheduled to release its Q1 2026 earnings before market open on Tuesday, May 12th, with analysts projecting a loss of ($0.52) per share. The company's stock has shown significant volatility with a 12-month range of $3.89–$36.26 and a beta of 2.05. Despite an average analyst consensus of "Moderate Buy" and a target price of $44.40, insiders have recently sold shares.
Five new Olema hires receive stock options at $14.32 a share
Olema Oncology (Nasdaq: OLMA) granted inducement stock options for an aggregate of 154,700 shares to five new employees, effective May 1, 2026. These options have a 10-year term, an exercise price of $14.32 per share, and vest over four years. The awards were made under the company’s 2022 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced that it granted stock options to five new employees to purchase an aggregate of 154,700 shares of its common stock, effective May 1, 2026. These inducement grants were made under the Company's 2022 Inducement Plan and in compliance with Nasdaq Listing Rule 5635(c)(4). The grants serve as a material inducement for the new employees to join Olema.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals, Inc. announced that it granted stock options to five new employees to purchase an aggregate of 154,700 shares of the Company's common stock. These awards were made effective May 1, 2026, under the Company's 2022 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years with a 10-year term and an exercise price of $14.32 per share.
Olema Adds Deal Veteran Prakash Raman To Guide Oncology Partnerships
Olema Pharmaceuticals (NasdaqGS:OLMA) has appointed Prakash Raman, Ph.D., to its Board of Directors to enhance its oncology partnership and acquisition strategy. Dr. Raman's extensive background in business development and his experience at Novartis are expected to guide Olema's approach to future collaborations and pipeline decisions. This move is intended to strengthen the company's ability to evaluate external opportunities and manage its early-stage, loss-making business effectively.
Pictet Asset Management Holding SA Trims Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA
Pictet Asset Management Holding SA significantly reduced its stake in Olema Pharmaceuticals (NASDAQ:OLMA) by 69.3% in the fourth quarter, selling over 1.1 million shares and retaining 502,568 shares worth approximately $12.6 million. Despite this, analysts generally maintain a "Moderate Buy" rating with an average price target of $44.40, significantly higher than the current trading price. The article also notes recent insider selling by Shawnte Mitchell and provides financial performance details for Olema Pharmaceuticals, a company focused on therapies for women's cancers.
Jennison Associates LLC Takes Position in Olema Pharmaceuticals, Inc. $OLMA
Jennison Associates LLC has acquired a significant stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA), purchasing nearly 1 million shares valued at approximately $24.1 million in Q4, representing 1.40% ownership. The biopharmaceutical company, focused on women's cancers, is largely favored by analysts, holding a consensus "Moderate Buy" rating and a target price of $44.40. Institutional investors now own 91.78% of the company, which is developing its lead candidate OP-1250 for ER+/HER2- breast cancer.
Olema Pharmaceuticals Signs New Headquarters Lease at Oyster Point
Olema Pharmaceuticals has signed a seven-year lease for a new 38,176 square-foot headquarters at Oyster Point, with plans to relocate from San Francisco by December 2026. The agreement involves over $18.5 million in base rent, with options for early termination, extension, and future expansion. Despite the move and a "Buy" analyst rating, TipRanks' AI Analyst, Spark, rates OLMA as Neutral due to widening losses, accelerated cash burn, and a bearish technical setup, offset by a strong balance sheet.
Olema Pharmaceuticals (NASDAQ: OLMA) inks 7-year HQ lease with $18.5M base rent
Olema Pharmaceuticals (NASDAQ: OLMA) has signed a seven-year lease for a new 38,176 square-foot headquarters in South San Francisco with KR Oyster Point II, LLC. The total base rent over the initial term is approximately $18.5 million, with Olema planning to relocate by December 2026 as current leases expire. The agreement includes a termination option at month 60 with a fee and an option for a five-year extension.
Executive pay and board seats on ballot at Olema (NASDAQ: OLMA) 2026 meeting
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) announced its 2026 Annual Meeting of Stockholders will be held virtually on June 17, 2026. Stockholders will vote on the election of four Class III directors, advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as the independent registered public accounting firm. The company's proxy statement details executive compensation, including base salaries, annual bonuses, equity awards, and severance provisions, along with information on director compensation and related person transactions.
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
Olema Oncology announced the appointment of Prakash Raman, Ph.D., to its Board of Directors. Dr. Raman brings over two decades of executive leadership and business development expertise in the biopharmaceutical industry. The company anticipates his experience will be integral as they advance lead programs and prepare for pivotal data from OPERA-01 this fall, transforming into a fully integrated oncology company.
Olema (NASDAQ: OLMA) director granted 27,061 stock options
Olema Pharmaceuticals director Raman Prakash has been granted 27,061 stock options as equity compensation, with an exercise price of $14.59 per share, expiring on April 27, 2036. The options vest based on continuous service, with one portion vesting in full on June 11, 2026, and another in 36 equal monthly installments starting April 28, 2026. This transaction reflects compensation rather than open-market purchases.
